Showing results (691-700 of 794) with videos related to

Sort By:
Pageof 80
Cancer|July 20, 2016
National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?Brandon A Mahal, Yu-Wei Chen, Vinayak Muralidhar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trialA Tripathi, Y Chen, D F Jarrard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United StatesB A Mahal, Y-W Chen, V Muralidhar, et al.
Molecular Oncology|May 28, 2025
Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumabCharles Swanton, Russell W Madison, Candice Francheska B Tambaoan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 5, 2006
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal functionAlain C Mita, Christopher J Sweeney, Sharyn D Baker, et al.
Urology|July 1, 2014
Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groupsBrandon A Mahal, Ayal A Aizer, David R Ziehr, et al.
Seizure|October 1, 2023
Vagus nerve stimulation in refractory idiopathic generalised epilepsy: An Irish retrospective observational studyJavier Peña-Ceballos, Patrick B Moloney, Antonio Valentin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsD J Jonker, L S Rosen, M B Sawyer, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
European Urology Oncology|December 12, 2024
Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate CancerMark C Markowski, Yi Ren, Meghan Tierney, et al.
Pageof 80